Vinge advised Apotea on the deal. Apotea AB (publ) completed its listing on Nasdaq Stockholm. The offering price was SEK 58 per ordinary share, corresponding to a...
You must be a Standard 1 Year member to access this content.
Vinge advised Egetis Therapeutics on the deal. Egetis Therapeutics AB (publ), listed on Nasdaq Stockholm, completed a directed share issuances whereby Egetis Therapeutics receives gross proceeds...
You must be a Standard 1 Year member to access this content.
Vinge advised Hansa Biopharma AB on the deal. Hansa Biopharma AB (publ) finalized a directed share issue through which the company raises proceeds of SEK 372 million...
You must be a Standard 1 Year member to access this content.
Vinge advised Triton on the deal. Triton completed the sale of shares in Ambea AB. In total, 7.7 million shares were placed at a price of SEK...
You must be a Standard 1 Year member to access this content.
Cederquist advised CDON on the deal. CDON and the majority shareholders of Fyndiq, two of the leading retail marketplaces in Sweden, have agreed to combine their...
You must be a Standard 1 Year member to access this content.
Simpson Thacher and Loyens & Loeff Luxembourg represented J.P. Morgan, Nordea, Morgan Stanley and DNB Markets who acted as underwriters on the deal, while Advokatfirman Cederquist...
You must be a Standard 1 Year member to access this content.
Skadden, Arps, Slate, Meagher & Flom (UK) LLP and Cederquist advised BillerudKorsnäs. Linklaters advised the Joint Global Coordinators and Joint Bookrunners. BillerudKorsnäs AB, (Nasdaq Stockholm: BILL),...
You must be a Standard 1 Year member to access this content.
Wikborg Rein and Cederquist assisted Aeternum on the deal. Aeternum Capital AS acquired 19.55 percent of the shares and 13.78 percent of the votes in SkiStar...
You must be a Standard 1 Year member to access this content.
YPOG and Blomstein advised Helsing on the deal. Cederquist and Raue advised Prima Materia. The European defence AI company Helsing announced the latest funding round with...
You must be a Standard 1 Year member to access this content.
